Moutih Rafei
Technik-/Wissenschafts-/F&E-Leiter bei DEFENCE THERAPEUTICS INC.
Vermögen: 61 390 $ am 30.04.2024
Aktive Positionen von Moutih Rafei
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| DEFENCE THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 05.01.2021 | - |
| Technik-/Wissenschafts-/F&E-Leiter | 09.10.2020 | - | |
| University of Montréal | Corporate Officer/Principal | - | - |
Karriereverlauf von Moutih Rafei
Ehemalige bekannte Positionen von Moutih Rafei
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
IntelliStem Technologies, Inc.
 IntelliStem Technologies, Inc. BiotechnologyHealth Technology IntelliStem Technologies, Inc. is a Canadian biotechnology company that specializes in engineering stem cells for the development of next-generation cell therapy products. The private company is based in Toronto, Canada. The company's proprietary cell platforms, including Super Sentinel Cells (SSCs) for cancer therapeutics and IntelliCells for drug discovery and target identification, are genetically engineered. IntelliStem is currently moving into human clinical trials. The company was founded by Riam Shammaa, who has been the CEO since incorporation. | Technik-/Wissenschafts-/F&E-Leiter | - | 01.08.2023 |
| Gründer | - | 01.08.2023 |
Ausbildung von Moutih Rafei
| McGill University | Doctorate Degree |
Statistik
International
| Kanada | 5 |
Operativ
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 2 |
| Director/Board Member | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| DEFENCE THERAPEUTICS INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
IntelliStem Technologies, Inc.
IntelliStem Technologies, Inc. BiotechnologyHealth Technology IntelliStem Technologies, Inc. is a Canadian biotechnology company that specializes in engineering stem cells for the development of next-generation cell therapy products. The private company is based in Toronto, Canada. The company's proprietary cell platforms, including Super Sentinel Cells (SSCs) for cancer therapeutics and IntelliCells for drug discovery and target identification, are genetically engineered. IntelliStem is currently moving into human clinical trials. The company was founded by Riam Shammaa, who has been the CEO since incorporation. | Health Technology |
- Börse
- Insiders
- Moutih Rafei
- Erfahrung
